A new trading day began on Friday, with Immuneering Corp (NASDAQ: IMRX) stock price down -4.31% from the previous day of trading, before settling in for the closing price of $1.16. IMRX’s price has ranged from $1.00 to $9.35 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -43.59% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -2.26%. With a float of $21.00 million, this company’s outstanding shares have now reached $29.27 million.
In an organization with 68 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.79%, operating margin of 64.04%, and the pretax margin is 59.38%.
Immuneering Corp (IMRX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immuneering Corp is 29.16%, while institutional ownership is 32.38%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,160,181. In this transaction 10% Owner of this company sold 400,000 shares at a rate of $2.90, taking the stock ownership to the 2,895,273 shares. Before that another transaction happened on Mar 22 ’24, when Company’s Director bought 2,900 for $2.55, making the entire transaction worth $7,385. This insider now owns 2,900 shares in total.
Immuneering Corp (IMRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -2.26% per share during the next fiscal year.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
Here are Immuneering Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.91, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.29 million. That was inferior than the volume of 0.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 76.00%. Additionally, its Average True Range was 0.10.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 9.44%, which indicates a significant decrease from 57.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.24% in the past 14 days, which was lower than the 90.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1906, while its 200-day Moving Average is $3.6249. However, in the short run, Immuneering Corp’s stock first resistance to watch stands at $1.1433. Second resistance stands at $1.1767. The third major resistance level sits at $1.1933. If the price goes on to break the first support level at $1.0933, it is likely to go to the next support level at $1.0767. The third support level lies at $1.0433 if the price breaches the second support level.
Immuneering Corp (NASDAQ: IMRX) Key Stats
With a market capitalization of 32.91 million, the company has a total of 29,653K Shares Outstanding. Currently, annual sales are 0 K while annual income is -53,470 K. The company’s previous quarter sales were 0 K while its latest quarter income was -14,080 K.
